Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease

Table 1 Clinical features of the total studied inflammatory bowel disease patients n (%)

Clinical features	Value
Age (yr, mean ± SD)	43.4 ± 13.8
Gender
Female	305 (51.70)
Male	285 (48.3)
Type of IBD
CD	313 (53.05)
UC	256 (43.39)
IBDU	21 (3.56)
Disease extension (UC)1
Proctitis	61 (23.83)
Left-sided colitis	124 (48.44)
Pancolitis	71 (27.82)
Age at diagnosis (CD)1
A1 < 17	24 (7.67)
A2 17-40	208 (66.45)
A3 > 40	81 (25.88)
Disease location (CD)1
L1 ileal	112 (35.78)
L2 colic	76 (24.28)
L3 ileocolic	111 (35.46)
L4 upper gastrointestinal tract	6 (1.92)
L1 + L4	5 (1.60)
L3 + L4	3 (0.96)
Behaviour (CD)1
B1 non-stricturing non-penetrating	179 (57.19)
B2 stricturing	30 (9.58)
B3 penetrating	41 (13.10)
B1 + perianal disease	51 (16.29)
B2 + perianal disease	1 (0.32)
B3 + perianal disease	11 (3.52)
Immunosuppressive or biological treatment
Thiopurines	259 (43.90)
Anti-TNF-α drugs	84 (14.23)

¹In accordance with the Montreal classification. IBD: Inflammatory bowel disease; IBDU: Inflammatory bowel disease type unclassified; CD: Crohn's disease; UC: Ulcerative colitis.